Back to search

University of Ioannina

Μελέτη της θεραπείας με ανοσοτροποιητικά φάρμακα και βιολογικούς παράγοντες σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων

Abstract

dc:description

Introduction: Therapeutic monitoring of infliximab correlates with improved outcomes in patients with inflammatory bowel diseases (IBD). This cross-sectional study aimed to assess the relationship between serum infliximab trough levels (TLs), antibodies-to-infliximab (ATI) and therapeutic outcomes in patients with ulcerative colitis (UC) and Crohn’s disease (CD) within a Greek population. The relationship between infliximab-related infusion reactions (IRs) and the presence of ATI was also investigated. Materials and Methods: Consecutive adult patients with IBD treated with intravenous maintenance infliximab at a Greek tertiary centre were included. Investigated therapeutic outcomes included sustained clinical remission (CR), steroid-free clinical remission (SFCR), biochemical remission (CRP <5mg/L, BR) and combined (steroid-free clinical and biochemical) remission (SFCBR). Infliximab TLs and ATI (in patients with TLs <1 μg/mL) were assessed using ELISA-based assays. Results: A total of 77 patients were enrolled (62.3% males, mean age 44 years), including 48 (62.3%) with CD, 26 (33.8%) with UC and 3 (3.9%) with unclassified colitis. The mean disease duration was 11.7 years and the mean duration of infliximab infusion was 5.1 years. Forty-seven patients (61%) had undergone treatment escalation with a decrease in infusion intervals, with a further dose escalation in 7 (9.1%) patients. Concomitant therapy was administered to 13 (16.8%) patients, with 4 (5.2%) receiving azathioprine and 9 (11.7%) corticosteroids. Mean infliximab TLs were 7.2±4.9 μg/mL, significantly correlating with treatment escalation (9.7 vs 3.6 μg/mL, p<0.001). Sixty-eight patients (88.3%) achieved CR, 62 (80.5%) achieved SFCR, 48 (62.3%) achieved BR and 43 (55.8%) achieved SFCBR. Mean infliximab TLs were higher, though not significantly, among responders. In the subgroup analysis, among patients without treatment escalation, 27 (90%) achieved CR, 25 (83.3%) achieved SFCR, 22 (73.3%) achieved BR and 19 (63.3%) achieved SFCBR. Mean infliximab TLs were significantly higher in patients with BR (4.2 vs 0.8 μg/mL, p=0.020) and SFCBR (4.3 vs 1.5 μg/mL, p=0.035). ROC analysis indicated that TLs could predict SFCBR (p=0.016) with good accuracy (AUC 0.768, 95% Cl: 0.584=0.952), with an optimal TL cut-off at 3.4 μg/mL. Among patients with treatment escalation, 41 (87.2%) achieved CR, 37 (78.7%) achieved SFCR, 26 (55.3%) achieved BR and 24 (51.1%) achieved SFCBR. ROC analysis indicated that TLs could predict SFCBR (p=0.018) with a fair accuracy (AUC 0.653, 95% CI: 0.527=0.755), with an optimal TL cut-off at 11 μg/mL. Of the 20 patients with TLs <1 μg/mL who had ATI measured, 10 had positive ATI. Among these 20 patients, 9 achieved combined remission, with 4 having positive ATI. In the 11 patients who did not achieve combined remission, 6 (54.5%) had positive ATI, indicating non-response to infliximab due to immunogenicity. Twenty-one patients (27.3%) reported adverse events, with 8 (10.4%) experiencing IRs attributed to infliximab. There was a tendency for IRs to correlate with ATI presence; 4 out of 5 patients who had IRs and measured ATI were positive, while out of 10 patients with positive ATI, 4 reported an IR, compared to 1 out of 10 patients with negative ATI (p=0.152).Conclusions: In this study we have shown that infliximab TLs are correlated with treatment escalation. Higher TLs seem to result in positive therapeutic outcomes. Furthermore, patients undergoing treatment escalation seem to benefit from higher infliximab TLs for achieving clinical and biochemical remission. Immunogenicity, as indicated by ATI, contributes to loss of response in some patients with low infliximab TLs. There is also a trend indicating a correlation between ATI and IRs.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Orfanidou, Afroditi
  • Ορφανίδου, Αφροδίτη

Subjects

dc:subject × 24

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/57790

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Orfanidou, Afroditi; Ορφανίδου, Αφροδίτη. Μελέτη της θεραπείας με ανοσοτροποιητικά φάρμακα και βιολογικούς παράγοντες σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων. University of Ioannina, 2024. http://hdl.handle.net/10442/hedi/57790